Rigel Pharmaceuticals RIGL

NAS: RIGL | ISIN: US7665596034 30/04/2025

19,56 USD (-0,05%)

(-0,05%) 30/04/2025

Grafiek Rigel Pharmaceuticals

Grafiek Rigel Pharmaceuticals

1 dag1d -0,05%
1 week1w 2,62%
1 maand1m 14,05%
3 maanden3m -7,56%
6 maanden6m 37,75%
1 jaar1j 1.694,50%
5 jaar5j 1.043,86%

Rigel Pharmaceuticals in het nieuws

Toon enkel gratis nieuws

29 april 2025 · Rigel Announces Conference Call and Webcast to Report First Quarter 2025 Financial Results and Business Update · Persbericht

4 april 2025 · Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) · Persbericht

27 maart 2025 · Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib disodium hexahydrate) Patent Litigation · Persbericht

10 maart 2025 · Rigel Appoints Mark W. Frohlich, M.D. to Board of Directors · Persbericht

4 maart 2025 · Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update · Persbericht

12 september 2024 · Rigel to Present at the 2024 Cantor Global Healthcare Conference · Persbericht

5 september 2024 · Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA® (olutasidenib) in mIDH1 AML · Persbericht

3 september 2024 · Rigel Expands Relationship with Kissei to include REZLIDHIA® (olutasidenib) in Japan, the Republic of Korea and Taiwan · Persbericht

29 augustus 2024 · Rigel to Participate in Upcoming September Investor Conferences · Persbericht

6 augustus 2024 · Rigel Reports Second Quarter 2024 Financial Results and Provides Business Update · Persbericht

Profiel Rigel Pharmaceuticals

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

Website: www.rigel.com

Hoofdzetel: South San Francisco, California Verenigde Staten

CEO: Raul Rodriguez

Werknemers: 280

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe